Feedback, always on the hunt for absurd units of measurement, is delighted by recent attempts to convey the 406,771 ...
Medicines360 and Pharma Dynamics have announced the availability of AVIBELA, South Africa’s first generic levonorgestrel 52 mg intrauterine device (IUD), marking a significant step forward in access ...
Medicines360 and Pharma Dynamics have announced the availability of AVIBELA, South Africa’s first generic levonorgestrel 52 mg ...
ATH434 reduced functional decline vs placebo at Week 52 on MuSyCA, a newly described MSA composite scale - - Effects seen on both daily function and neurological examination, consistent with ...
New drugs approved in 2025 are poised to significantly improve the management of motion sickness, acute pain, urinary tract infections (UTIs), and chronic spontaneous urticaria. Gerald W. Smetana, MD, ...
Merck built a wall of patents that keeps a cancer drug's price – and its profits – high. Hospitals often add to the cost for ...
Pliant Therapeutics, Inc. (Nasdaq: PLRX) today announced the presentation of updated data from its Phase 1 trial of ...
Filing acceptance based on Phase III ALLEGORY data for Gazyva showing a significant reduction in disease activity compared with placebo in people with systemic lupus erythematosus (SLE)If approved, ...
STRO-004 demonstrates robust and consistent antitumor activity across multiple TF-expressing solid tumor PDX models, with improved efficacy ...
The US Food and Drug Administration (FDA) has issued warning letters to several drug manufacturers and compounders for ...
Sixth paragraph, fifth sentence of release issued April 20, 2026 at 10 p.m. PT/April 21, 2026 at 1 a.m. ET, should read: In addition, treatment with Gazyva plus standard therapy, versus placebo plus ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results